Day: March 30, 2021

ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2021. Posted in Earnings Releases And Operating Results.

Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research and Development Authority (BARDA) contract award provides up to $86.8 million for exebacase Phase 3 development Company raised $57.5 million in public offering; strong cash position to support development of exebacase, as well as the advancement of preclinical lysin and amurin peptide programs YONKERS, N.Y., March 30, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced...

Arvopaperimarkkinalain 9 luvun 10 pykälän mukainen ilmoitus omistusosuuden muuttumisesta

Written by Customer Service on March 30, 2021. Posted in Public Companies.

ELECSTER OYJ PÖRSSITIEDOTE (LIPUTUSILMOITUS)30.03.2021 klo 14:30 ARVOPAPERIMARKKINALAIN 9 LUVUN 10 PYKÄLÄN MUKAINEN ILMOITUS OMISTUSOSUUDEN MUUTTUMISESTA Elecster Oyj on tänään 30.03.2021 vastaanottanut Jukka Halosen ja Irma Halosen AML 9 luvun 9 §:n mukaiset ilmoitukset. Jukka Halosen prosenttiosuus osakkeista on ilmoituksen mukaan11,49 % ja äänistä 19,74 %. Vastaavasti Irma Halosen osuus on ilmoituksen mukaan0,00 % sekä osakkeista että äänistä.Jukka Halosen kokonaisosuus yhtiön osakkeista ja äänistä ilmoituksen mukaan: % osakkeista % äänistä kohdeyhtiön osakkeiden kokonaismäärä kohdeyhtiön äänten kokonaismääräOsuus liputusrajan saavuttamisen jälkeen 11,49 % 19,74 % 3 748 116 21 100 116Osakkeet ja äänet liputusrajan saavuttamisen jälkeen, Jukka Halonen Osakesarja/-laji Osakkeiden lukumäärä Osakkeiden...

Innoviz and Collective Growth Count Down to Wednesday’s Vote

Written by Customer Service on March 30, 2021. Posted in Public Companies.

AUSTIN, Texas, March 30, 2021 (GLOBE NEWSWIRE) — Collective Growth Corporation (NASDAQ: CGRO) (“Collective Growth”) reminds stockholders that the Special Meeting of Stockholders of Collective Growth (the “Special Meeting”) to approve the pending business combination between Collective Growth and Innoviz Technologies Ltd. (INVZ) (“Innoviz”) is scheduled to be held on Wednesday, March 31, 2021, at 9:00 a.m., Eastern time. Whether or not you plan to attend the virtual Special Meeting in person and regardless of the number of shares you may own, we urge you to vote FOR ALL proposals. CHECK YOUR EMAIL FOR VOTING! If you hold shares at Robinhood or Interactive Brokers from Proxydocs.com For all others check for an email from Proxyvote.com Vote by Telephone: Follow the instructions provided by your...

Tiziana Life Sciences plc: Accustem Update

Written by Customer Service on March 30, 2021. Posted in Public Companies.

NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribution of shares in Accustem Sciences Limited (“Accustem“) to the holders of Tiziana shares in the US via its ADS program, it has recently filed a Form 20-F with the Securities Exchange Commission in the USA (the “SEC“). The Form 20-F (which gives full information about the business of Accustem), can be found at https://sec.report/CIK/0001850767. Once the SEC has approved the Form 20-F (or it becomes effective), the final aspect of the distribution will be complete and Accustem will be an entirely separate entity and will move forward...

Odyssey Group International Welcomes World Cup Winner Abby Wambach to Sports Advisory Board

Written by Customer Service on March 30, 2021. Posted in Public Companies.

Irvine, CA, March 30, 2021 (GLOBE NEWSWIRE) — Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products, is honored to welcome retired United States National Soccer Team captain Abby Wambach to its Sports Advisory Board (SAB). The inaugural members of the SAB include notable professional athletes who have a passion to advance treatments for brain injuries. Wambach is a two-time Olympic gold medalist, World Cup champion, and winner of the FIFA World Player of the Year. A six-time winner of the U.S. Soccer Athlete of the year, she is the record goal scorer for both the Men’s and Women’s National Soccer Teams. Internationally, Wambach is the second highest goal scorer of all time. Wambach...

International development strategy pursuit in Asia and in the United States

Written by Customer Service on March 30, 2021. Posted in Public Companies.

Press release Ecully, 29 March 2021 – 6 p.m. Continued international developmentWorkshop in Thailand dedicated to Spineway implants and instruments Signature of a distribution agreement in the United StatesSpineway, specialized in the design of innovative surgical implants and instruments for the treatment of severe disorders of the spine, continues its international development with the organization of a workshop in Thailand on the use of its products, and the signature of a distribution agreement in the US state of Ohio. About fifty spinal surgeons met on 17 March 2021 at the Faculty of Medicine in Khon Kaen, Thailand, for a workshop on the use of the surgical implants and instruments sold by Spineway. Led by a senior surgeon, this workshop allowed...

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Written by Customer Service on March 30, 2021. Posted in Earnings Releases And Operating Results.

Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patientsEnrollment across clinical ACTengine® IMA200 trial series continues to scale upCash and cash equivalents as well as other financial assets of $285 million1(€232 million) as of December 31, 2020 provide cash reach into 2023Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2020. Harpreet Singh, Ph.D., CEO of Immatics commented, “The past year was exceptional...

Immatics veröffentlicht Ergebnisse des Geschäftsjahres 2020 sowie ein Update zur Geschäftsentwicklung

Written by Customer Service on March 30, 2021. Posted in Earnings Releases And Operating Results.

Erste Anti-Tumorwirkung in den ACTengine® Phase 1a-Studien gezeigt Patientenrekrutierung für die klinischen ACTengine® Studien in Deutschland und USA weiter ausgebaut Zum 31. Dezember 2020 verfügte Immatics über liquide Mittel in Höhe von 285 Millionen US-Dollar1(232 Millionen Euro), damit sind die Betriebskosten voraussichtlich bis in 2023 hinein gedecktTübingen, Deutschland und Houston, Texas, USA, 30. März 2021 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-basierten Immuntherapien für die Behandlung von Krebs fokussiert, gab heute die Ergebnisse für das 4. Quartal und das gesamte Geschäftsjahr 2020 sowie ein Update zur weiteren Geschäftsentwicklung bekannt. Harpreet Singh, Ph.D., CEO von Immatics, kommentierte: „2020 war ein ganz besonderes Jahr für Immatics....

Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Written by Customer Service on March 30, 2021. Posted in Earnings Releases And Operating Results.

MIAMI, March 30, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and full year ended December 31, 2020 and provided a business update. Primary Accomplishments in 2020:Received approval from U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical trial for Acute Respiratory Distress Syndrome (ARDS) related to either COVID-19 or Influenza infection. This trial initiated in mid-2020 and continues to enroll subjects. Received a $650,000, two-year Maryland Stem Cell Research Fund TEDCO Grant Award for ARDS COVID-19/Influenza Phase 1 trial. Treated two COVID-19-related ARDS subjects...

Nubeva Announces Q3 Fiscal 2021 Financial Results

Written by Customer Service on March 30, 2021. Posted in Earnings Releases And Operating Results.

SAN JOSE, Calif., March 30, 2021 (GLOBE NEWSWIRE) — Nubeva Technologies Ltd. (“Nubeva” or the “Company“) (TSX-V: NBVA), announces its unaudited consolidated financial statements for the Three and Nine Months ended January 31, 2021. Financial statements along with management discussion and analysis of financial results can be found at www.sedar.com. All dollar amounts in this release are quoted in U.S. Dollars. During the third quarter Nubeva reported revenue of $766,709 compared with revenue from the same quarter of last year of $40,117. This brings nine-month revenue to $1,734,024, up from revenue of $117,784 for the comparable nine-month period. The increase in revenue for the quarter and the nine months was due to the recognition of revenue from the Company’s license of its Symmetric Key Intercept software...

Day: March 30, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals